Get Lit: Cannabis Infused Cocktails From Wellness Brand 1906 For 4/20
Smoking cocktail
From medicinal to recreational use, cannabis has evolved, appearing in various forms such as sweet treats, gummies, pills, salves, creams and more. As the search for alternatives to alcohol consumption grows, cannabis-infused drinks are stepping into the limelight. The cannabis drink culture is a growing trend, with these beverages gaining popularity not only as a wellness alternative to alcohol but also as a social experience. Aside from being a trending alternative to normal alcoholic beverages, the popularity of the trend can also be attributed to a number of places legalizing it. The global cannabis beverages market is not just a future prospect. It's already made a significant impact with a market size of 2.04 billion in 2023. And this is just the beginning, as it is projected to grow to 117.05 billion by 2032.
With a steadfast dedication to wellness, 1906 promotes the use of cannabis products for their health benefits. The brand is named after the last time cannabis was deemed acceptable as a beneficial medicine: the year 1906.
1906 Bliss Drops
They have quite an impressive product line including sleep aids, stress relievers, pain relief, energy boosters, euphoric mood enhancers and even a little something to help with the libido. One of the other benefits is that all of 1906's products are fast-acting, vegan and gluten-free. They also contain zero sugar and calories. For anyone new to cannabis usage or diving into the world of micro dosing, they can be a solid and safe option. However, my personal favorite is the Off-Duty Cannabis Shots!
Disclaimer: Before using any product, please consult your healthcare professional about potential interactions or other possible complications.
Whether it's a refreshing lemonade, a creamy matcha or a cold glass of sweet tea, I've often found myself wanting a drink that's tailored to my taste. While pre-made canned beverages are convenient, they can lack that personal touch. Off-Duty, on the other hand, allows you to personalize your favorite drink, making it truly yours.
1906 Off Duty Drink Packet
Off Duty, a flavorless cannabis shot, is a healthier alternative to traditional alcoholic beverages. It's designed to blend seamlessly into any drink, from your morning smoothie to your evening mocktail, and it's quick-acting, with effects in as little as 20 minutes. Although, in my experience, it felt even faster. And the best part? No more dealing with those pesky hangovers the next day. Each packet of Off Duty contains a gentle dose (5mg THC + 5mg CBD), ensuring a soothing state of calm and relaxation. The effects off these cannabis packs lasts abouto 45 minutes and the brand likens it to having a glass of wine or a light beer. It's just enough to take the edge off and helps you loosen up a bit. However, I still highly encourage (see what I did there? Ha ha) to consume Off Duty in a safe space, as everyone's body can have different effects.
It may feel strange to have a holiday dedicated to the consumption of marijuana, but this Sunday, or April 20, that's precisely what millions will be celebrating. If you're looking for something new to spice it up, consider leaning into the cannabis drink culture and trying one of these high-quality and delicious recipes from 1906's Off Duty.
Espresso Tonic
Shirley Temple Mocktail
However you choose to celebrate 4/20, we hope it's a blast!
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
12 hours ago
- Forbes
Medtronic Announces Intent To Spin Diabetes Business
(Photo Illustration by) Deal OverviewOn May 21, 2025, Medtronic plc (NYSE: MDT; $87.44, Market Capitalization: $112.1 billion), a global leader in medical technology, announced its intent to spin off its Diabetes business into a standalone entity (New Diabetes Company). This strategic move is designed to streamline Medtronic's portfolio, sharpen its focus on high-margin growth areas, and unlock shareholder value. Post spin-off, Medtronic (RemainCo) will continue to operate as a diversified MedTech innovator, concentrating on its core franchises in cardiovascular, neuroscience, surgical, and medical-surgical technologies. Further, the company aims to accelerate growth through innovation in areas like pulsed field ablation, renal denervation, soft tissue robotics, and neuromodulation. Meanwhile, the New Diabetes Company (NewCo) will be offering a complete ecosystem for intensive insulin management, including insulin pumps, continuous glucose monitoring (CGM), and digital health solutions. The separation is expected to be completed within 18 months, primarily through a capital markets transaction, with a preferred path of an initial public offering (IPO) followed by a split-off. The transaction is expected to be tax-free to Medtronic shareholders for US federal income tax purposes. The separation will include the Diabetes business employees, product portfolio, pipeline, intellectual property, strategic partnerships, and global manufacturing facilities. Medtronic Price Performance Spin-Off Details and Top 5 Shareholders The transaction is anticipated to be accretive to Medtronic's gross and operating margins, and earnings per share, while enabling the NewCo to pursue focused innovation and growth strategies tailored to the diabetes market. It is also expected to provide the ability to retire Medtronic shares outstanding without reducing cash, resulting in EPS accretion and a reduction in the dividend liability for Medtronic, enabling increased growth-accretive investment. Medtronic expects its dividend per share to remain unchanged pre- and post-transaction with no change to its dividend policy. The spin-off is subject to customary regulatory approvals, board consent, and market conditions. Que Dallara, current EVP and president of Medtronic Diabetes, will become CEO of New Diabetes Company. Goldman Sachs & Co. LLC and BofA Securities, Inc. are acting as financial advisors to Medtronic in its review of strategic alternatives for the New Diabetes Company. Key Data Deal Rationale Medtronic, a global leader in MedTech, is planning to spin off its Diabetes business into a standalone entity, as part of a strategic move to sharpen its focus on higher-margin, faster-growing segments such as Cardiovascular, Neuroscience, and Medical-Surgical, which together account for over 90.0% of its total revenues. The Diabetes segment, contributing approximately $2.5 billion in FY25 (about 8.0% of Medtronic's total $32.4 billion in revenue), has consistently underperformed over the past five years, with a revenue CAGR of just ~1.4% compared to Medtronic's overall ~2.9% CAGR. Segment profitability has also lagged: while Medtronic's overall operating margin stands at ~15.9%, the diabetes unit has been a drag, reportedly generating operating losses in the low teens in its core U.S. market. In FY19, the segment posted a strong operating margin of 30.9% but steadily declined to 24.8–24.9% through FY21 and FY22, before dropping significantly to 15.8% in FY25. Multiple headwinds contributed to this underperformance, including FDA regulatory setbacks, such as the 2021 warning letter and delayed approval of the MiniMed 780G insulin pump and Guardian 4 sensor, alongside intensifying competition from more agile players like Dexcom, Abbott, Tandem, and Insulet. These rivals outpaced Medtronic with faster innovation in continuous glucose monitoring (CGM) and closed loop insulin delivery systems. Furthermore, the rising adoption of GLP-1 receptor agonists (e.g., Ozempic, Mounjaro) is shifting treatment paradigms, particularly for Type 2 diabetes, reducing demand for insulin pumps. Despite a recent rebound, with the diabetes segment growing ~10.7% YoY in FY25 and six consecutive quarters of double-digit growth, the improvement is seen as insufficient to offset the structural challenges and lower returns relative to the rest of Medtronic's portfolio. By spinning off the diabetes business, Medtronic aims to lift its gross margin by approximately 50 basis points, adjusted operating margins by approximately 100 basis points, and be immediately accretive to adjusted EPS. As per management, following this separation, Medtronic is expected to increase focus on innovation-driven growth and category leadership for healthcare systems and physician customers. The company will have enhanced benefit from its scale and strategic commercial, manufacturing, and technology synergies. On the other hand, this separation is expected to enable more focused investment into New Diabetes Company's pipeline, as well as manufacturing scale and automation, positioning the company for success in Automated Insulin Delivery and Smart MDI, while driving margin expansion over time. At the same time, it will create an independent, scaled leader in Diabetes, focused on accelerating innovation and differentiated as the only company to commercialize a complete ecosystem to address intensive insulin management. The separation is also expected to unlock value for Medtronic and its shareholders, as it creates a New Diabetes Company shareholder base more aligned with its financial profile. Medtronic plc is a global healthcare technology leader that designs and manufactures medical devices and therapies to treat a wide range of chronic and acute health conditions. The company operates in over 150 countries and focuses on improving patient outcomes through innovation in areas such as AI, robotics, and data-driven care. Medtronic's operations are structured into four major segments, each addressing a distinct area of healthcare technology. The Cardiovascular segment includes heart rhythm devices, heart valves, and vascular therapies for treating cardiac and circulatory conditions. The Neuroscience segment offers spinal implants, stroke treatment devices, and neuromodulation systems for managing neurological and musculoskeletal disorders. The Medical Surgical segment provides surgical tools, robotic-assisted systems, and patient monitoring technologies, while the Diabetes segment delivers insulin pumps, continuous glucose monitoring systems, and smart insulin pens to help manage diabetes effectively. Cardiovascular: The Cardiovascular segment is dedicated to treating heart and vascular diseases through advanced medical technologies. It includes three subsegments: Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, and Coronary & Peripheral Vascular. This segment offers pacemakers, implantable defibrillators, heart valves, ablation systems, and vascular stents. In FY25, it generated $12.4 billion in revenue (37.2% of total revenue), growing 5.5%. Medtronic continues to lead in innovations like leadless pacing and pulsed field ablation, addressing both chronic and acute cardiac conditions globally. • Cardiac Rhythm & Heart Failure (CRHF): CRHF focuses on devices tha manage abnormal heart rhythms and heart failure. It includes pacemakers like the Micra leadless system, implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy (CRT) devices, and insertable cardiac monitors. The segment also includes cardiac ablation systems and remote monitoring services.• Structural Heart & Aortic (SHA): SHA provides solutions for heart valve disorders and aortic diseases. It includes transcatheter aortic valve replacement (TAVR) systems like Evolut FX, surgical heart valves, perfusion systems, and endovascular stent grafts. These devices are used in both minimally invasive and open-heart procedures.• Coronary & Peripheral Vascular (CPV): CPV delivers therapies for coronary artery disease and peripheral vascular conditions. It includes druge luting stents (e.g., Onyx Frontier), angioplasty balloons, renal denervation systems (e.g., Symplicity Spyral), and venous disease treatments like VenaSeal. Neuroscience: The Neuroscience segment addresses neurological and musculoskeletal disorders through surgical and therapeutic technologies. It includes Cranial & Spinal Technologies, Specialty Therapies, and Neuromodulation. This segment integrates robotics, AI, and navigation systems to improve surgical precision and patient outcomes. In FY25, it generated $9.8 billion in revenue (29.4% of total revenue), growing 4.7%. Medtronic's innovations in spine surgery, stroke treatment, and neuromodulation continue to drive global adoption. • Cranial & Spinal Technologies (CST): CST develops surgical solutions for spine and cranial procedures. It includes implants, biologics, and enabling technologies like Mazor robotics, StealthStation navigation, and UNiD AI-driven planning. These tools help surgeons perform complex procedures with greater accuracy.• Specialty Therapies: This subsegment includes neurovascular, ENT (ear, nose, and throat), and pelvic health therapies. It offers stroke treatment devices like Solitaire and Pipeline, sinus implants like Propel, and bladder control systems like InterStim. These minimally invasive solutions address critical conditions and improve quality of life.• Neuromodulation: Neuromodulation provides implantable systems for managing chronic pain, movement disorders, and epilepsy. It includes spinal cord stimulators (e.g., Intellis, Inceptiv), deep brain stimulation (e.g., Percept), and drug infusion pumps (e.g., SynchroMed). These technologies personalize therapy using real-time Surgical: The Medical Surgical segment supports hospitals and surgical centers with advanced tools and monitoring systems. It includes Surgical & Endoscopy and Acute Care and Acute Care & Monitoring sub-segments. This segment offers robotic-assisted surgery, AI-powered endoscopy, and patient monitoring solutions. In FY25, it generated $8.4 billion in revenue (25.1% of total revenue), a decrease of 0.1%.• Surgical & Endoscopy (SE): SE provides advanced surgical instruments and digital surgery platforms. It includes stapling systems (e.g., Tri-Staple), vessel sealers (e.g., LigaSure), robotic-assisted surgery (Hugo RAS), and AI-powered endoscopy (GI Genius). These tools enhance surgical precision and efficiency.• Acute Care & Monitoring (ACM): ACM focuses on patient monitoring and respiratory care. It includes pulse oximetry (Nellcor), capnography (Microstream), airway management (Shiley), and brain monitoring (BIS). These solutions help clinicians manage critical care and reduce complications. Diabetes: The Diabetes segment is dedicated to managing Type 1 and Type 2 diabetes through smart, connected technologies. It includes insulin pumps (e.g., MiniMed 780G), continuous glucose monitoring (CGM) systems (e.g., Guardian), and smart insulin pens (e.g., InPen). In FY25, the segment generated $2.8 billion in revenue (8.2% of total revenue), growing 10.7%. Medtronic's diabetes solutions aim to automate insulin delivery and simplify disease management. The MiniMed 780G system features SmartGuard technology, which adjusts insulin every 5 minutes and includes a meal detection algorithm. The Guardian CGM system provides real-time glucose data, while the InPen smart pen integrates with CGM to guide dosing. Medtronic is focused on expanding access to automated insulin delivery systems and competing with pharmaceutical alternatives by emphasizing long-term glycemic control and patient empowerment. Revenue Trend and Adjusted Operating Profit vs. Margin Trend 4Q25 Total revenue grew by 3.9% YoY to $8.9 billion (+1.1% vs. consensus), driven by strong performance in Cardiovascular and Diabetes segments. International markets and new product launches made significant contributions to the growth. Cardiovascular segment revenue grew 6.6% YoY to $3.3 billion, driven by a 9.2% YoY increase in the Cardiac Rhythm & Heart Failure segment, a 6.9% YoY increase from the Structural Heart & Aortic segment, offset by a 0.2% YoY decline in the Coronary & Peripheral Vascular segment. Neuroscience segment revenue increased 2.9% YoY to $2.6 billion, driven by a 4.0% YoY increase in the Cranial & Spinal Technologies segment, a 9.5% YoY increase in the Neuromodulation segment, offset by a 2.4% YoY decline in the Specialty Therapies segment. Medical Surgical segment revenue improved 0.6% YoY to $2.2 billion, driven by a 0.2% YoY increase in the Surgical & Endoscopy segment, and a 6.3% YoY increase in the Acute Care & Monitoring segment. Diabetes segment revenue grew 10.3% YoY to $728.0 million, driven by strong US adoption of the MiniMed 780G system with high Continuous Glucose Monitor attachment and international pump upgrades to the Simplera Sync sensor. Adjusted operating income grew 7.6% YoY to $2.5 billion (-0.3% vs. consensus), and the corresponding margin improved ~94 bps to 27.8%, driven by strong revenue growth across key portfolios and disciplined expense management. Operating leverage from higher sales and lower SG&A as a percentage of revenue also contributed to margin expansion. Adjusted net income increased 7.8% YoY to $2.1 billion (+2.7% vs. consensus), and the corresponding margin grew ~84 bps to 23.3%. Adjusted diluted earnings per share came in at $1.62 (4Q24: $1.46), beating the consensus estimates by 2.7%. 4Q25 Revenue FY25 Total revenue grew by 3.6% to $33.5 billion (+0.1% vs. consensus), driven by strong performance in Cardiovascular and Diabetes segments, with notable growth in Cardiac Ablation. Continued innovation, international expansion, and new product approvals also supported overall growth. Cardiovascular segment revenue grew 5.5% to $12.5 billion, driven by a 6.6% increase in the Cardiac Rhythm & Heart Failure segment, a 2.3% increase from the Coronary & Peripheral Vascular segment, offset by a 0.1% decline in the Structural Heart & Aortic segment. Neuroscience segment revenue increased 4.7% to $9.9 billion, driven by a 4.6% increase in the Cranial & Spinal Technologies segment, a 10.7% increase in the Specialty Therapies segment, and a 1.2% growth in the Neuromodulation segment. Medical Surgical segment revenue declined 01% to $8.4 billion, due to 0.2% decline in the Surgical & Endoscopy segment, and offset by 0.1% growth in the Acute Care & Monitoring segment. Diabetes segment revenue grew 10.7% to $2.7 billion. Adjusted operating income grew 4.5% to $8.6 billion (in line with consensus), and the corresponding margin improved ~23 bps to 25.8%, driven by strong revenue growth and lower SG&A expenses. Adjusted net income increased 2.3% to $7.1 billion (+0.8% vs. consensus), while the corresponding margin contracted ~27 bps to 21.1%. Adjusted diluted earnings per share came in at $5.49 (FY24: $5.20), beating the consensus estimates by 0.6%. FY25 Revenue Company DescriptionMedtronic plc (Parent) Medtronic plc, headquartered in Galway, Ireland, is the world's leading healthcare technology company, committed to alleviating pain, restoring health, and extending life. With over 95,000 employees across more than 150 countries, Medtronic delivers innovative solutions for more than 70 health conditions. The company operates through four primary segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. These segments encompass a wide range of technologies, including cardiac rhythm devices, spinal and brain therapies, surgical tools, and insulin delivery systems. New Diabetes Company (Spin-Off) The New Diabetes Company will emerge as a leading global direct-to-consumer diabetes care provider, uniquely offering a comprehensive ecosystem for intensive insulin management. With a portfolio that includes insulin pumps, continuous glucose monitoring (CGM) systems, and digital health solutions, it empowers individuals to manage diabetes with greater ease and freedom. Backed by a dedicated team of over 8,000 employees and a robust global infrastructure, the company is poised to accelerate innovation in Automated Insulin Delivery and Smart Multiple Daily Injections (MDI). Organization Structure
Yahoo
02-06-2025
- Yahoo
Rainfall in May and returning heat is perfect environment for thousands of mosquitoes in Arkansas
LITTLE ROCK, Ark. – If you've had any BBQ's or bonfires outside lately, you may have noticed them. Pesky mosquitoes come back every summer, but this year it may be worse. According to the insect repellent company 'Off', Arkansas is under a high mosquito risk for May 30 – June 2, with a severe level expected by Monday and Tuesday. Andrea McNutt is one of many Arkansans feeling the effects of the Natural State's persistent rainfall from May. 'Like, I'm some kind of mosquito magnet or something,' McNutt said. Arkansas Storm Team Blog: Mosquito Mayhem Ahead for Arkansas While the sun has returned, some lingering puddles of water have become the new home to thousands of mosquitoes. One woman said it's becoming unbearable. 'They're horrible. I can't even sit out on my porch and drink my coffee. Within five minutes I'm swarmed,' Holly Hipple said. But there are some ways to try and keep mosquitoes from biting. Of course, one example is mosquito repellent. 'I don't like to go out a whole lot. And if I do, I'm spraying down with 'Off',' McNutt said. Philippine village battles dengue by offering bounties for mosquitos — dead or alive Other ways to try and avoid mosquitoes are clearing out clogged gutters and drains, and keeping your pool treated or covered and making sure nothing in your yard is holding standing water. This, mixed with the returning heat, can quicken a mosquito's life cycle. 'I had to dump my bird bath the other day. It was full and we left the tractor bucket up and it was full of mosquito larvae,' Hipple said. But the return of warmer weather is something these insects are going to have to share. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
31-05-2025
- Yahoo
Valerie Mahaffey death: Young Sheldon and Desperate Housewives star dies aged 71
Emmy-winning actor Valerie Mahaffey has died at age 71. The Young Sheldon and Desperate Housewives star, who had been diagnosed with cancer, died May 30, her husband Joseph Kell confirmed. 'I have lost the love of my life, and America has lost one of its most endearing actresses. She will be missed,' Kell said in a statement, per Variety. Born in Indonesia, Mahaffey got her start on Broadway, appearing in six plays and musicals in the 1970s and 80s. She appeared in more than a dozen off-Broadway and regional productions as well, including Othello opposite Morgan Freeman and Romeo and Juliet with Tom Hulce. After establishing herself as a versatile stage actor, Mahaffey became in-demand among TV and film productions. Mahaffey's first TV break came on the daytime soap opera The Doctors, for which she was nominated for a Daytime Emmy Award in 1980. She would go on to win the 1992 supporting actress Emmy for her work on Northern Exposure. Mahaffey played Eve in the comedy-drama, which aired on CBS from 1990-1995. Mahaffey's other notable TV roles included Alma Hodge on season three of Desperate Housewives, teacher Victoria MacElroy on Young Sheldon, and Helen Pergman on Big Sky. She guest starred on dozens of shows throughout her career including Cheers, CSI, Seinfeld, Wings, ER, The Mindy Project, Grey's Anatomy, Hannah Montana, and Boston Legal. Her film credits included roles in Jungle 2 Jungle, My First Wedding, Sully, and this year's Apple TV thriller, The 8th Day. She gained acclaim for the 2020 indie film French Exit with Michelle Pfeiffer and Lucas Hedges, earning her an Independent Spirit Award nomination. Fans saddened to hear word of Mahaffey's passing shared tributes on social media. 'Nobody could play CRAZY like Valerie Mahaffey. Desperate Housewives was INSANE,' one fan shared with a clip of Mahaffey in a scene with Marcia Cross. 'RIP Valerie Mahaffey. Thanks for all the laughs,' another wrote. 'RIP to a wonderful character actress. No matter the episode count or number of lines she would have, Valerie Mahaffey made an impression. Loved her as Frasier's secretary & on Big Sky,' another said. Someone else wrote: 'Valerie Mahaffey was always JUST right no matter what she was working in. Always so memorable, talented. I can't believe she was even 71 as that means she really was a part of my life watching things as long as I've been around. Grateful for her good work always.'
